Literature DB >> 11146571

Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders.

S Y Yoon1, A Tefferi, C Y Li.   

Abstract

BACKGROUND AND OBJECTIVES: Basic fibroblast growth factor (bFGF) is a multifunctional cytokine that exerts positive regulation in hematopoiesis and that may also have a role in myelofibrosis and angiogenesis. We used bone marrow immunohistochemical stains to obtain additional insight into the cellular distribution of bFGF in both chronic myeloproliferative diseases (CMPD) and myelodysplastic syndrome (MDS). DESIGN AND METHODS: Bone marrow immunohistochemical stains were used to evaluate the cellular distribution of bFGF in 29 patients with CMPD, 31 patients with MDS, and 5 normal controls.
RESULTS: The density of bFGF-expressing stromal cells was markedly increased in 74% of the patients with MDS, compared with in only 3% of those with CMPD. In contrast, the density was markedly decreased in 62% of the patients with CMPD (versus 6% in MDS). The staining pattern in normal controls was similar to that in patients with MDS. The presence or absence of associated bone marrow fibrosis did not influence the particular pattern of bFGF expression in either MDS or CMPD. INTERPRETATION AND
CONCLUSIONS: These observations suggest that bone marrow stromal cell bFGF expression in patients with CMPD is abnormally decreased and that the particular staining pattern may complement the morphologic distinction between CMPD and MDS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11146571

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  10 in total

Review 1.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

2.  Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Authors:  Elie Traer; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Jacqueline Martinez; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 3.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 4.  The role of morphology, cytochemistry and immunohistochemistry in the diagnosis of chronic myeloproliferative diseases.

Authors:  Chin-Yang Li
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Bone marrow expression and plasma concentration of basic fibroblast growth factor in patients with idiopathic thrombocytopenic purpura.

Authors:  Bora Son; Kyeong Seob Shin; Sook Young Bae; Soo-Young Yoon
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

6.  [Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia].

Authors:  H M Kvasnicka; J Thiele; P Staib; K Engels; S Kriener; A Schmitt-Graeff
Journal:  Pathologe       Date:  2004-03       Impact factor: 1.011

7.  Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans.

Authors:  Sung O Park; Heather L Wamsley; Kyungmi Bae; Zhongbo Hu; Xiaomiao Li; Se-woon Choe; William B Slayton; S Paul Oh; Kay-Uwe Wagner; Peter P Sayeski
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

8.  Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis.

Authors:  Ying Han; Lanzhu Yue; Max Wei; Xiubao Ren; Zonghong Shao; Ling Zhang; Ross L Levine; Pearlie K Epling-Burnette
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

Review 9.  Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Betty Tai; Sathyen A Prabhu; Catherine M Capac; Matthew Gliksman; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-12

10.  FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

Authors:  Elie Traer; Jacqueline Martinez; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Tibor Kovacsovics; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.